Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy

What is the frequency of second primary malignant neoplasms (SPMs) in patients receiving T-cell–engaging bispecific antibodies for B-cell lymphoma or multiple myeloma?In this systematic review and meta-analysis of 20 studies (26 cohorts; 2551 patients) with a median follow-up of 17.4 months, pooled SPM frequencies were 3.5% for total SPMs reported, 2.2% for SPMs leading to treatment discontinuation, and 1.4% for SPMs reported as causes of death.SPMs are a measurable complication in patients with lymphoma or myeloma receiving bispecific antibodies, but their frequency is challenging to estimate due to heterogeneous outcome definitions and inconsistent reporting, supporting the need for standardized long-term safety surveillance.

Corresponding Author: Roni Shouval, MD, PhD, Precision Cellular Therapy Laboratory, Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 (shouvalr@mskcc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.